ImmunityBio, Inc. (IBRX) vs Krystal Biotech, Inc. (KRYS)
- ImmunityBio, Inc. IBRX 9.18 −8.20%
- Krystal Biotech, Inc. KRYS 316.58 −4.07%
ImmunityBio, Inc. and Krystal Biotech, Inc. are both Biotechnology companies. ImmunityBio, Inc. and Krystal Biotech, Inc. are of similar size ($10.6B and $9.8B). ImmunityBio, Inc. has negative trailing earnings, so its P/E is not meaningful; Krystal Biotech, Inc. trades at 38.3×. ImmunityBio, Inc. grew revenue faster over the last twelve months: 192.9% against 22.6%. Krystal Biotech, Inc. has the higher net margin (54.8% vs −598.6%) and the higher return on invested capital (24.1% vs 0.00%). Across the 16 metrics below, Krystal Biotech, Inc. leads on 12 and ImmunityBio, Inc. on 4.
Valuation
Profitability
| Metric | IBRX | KRYS | Biotechnology median |
|---|---|---|---|
| Gross margin | 99.34% | 94.64% | 65.16% |
| Operating margin | (151.88%) | 44.89% | 0.00% |
| Net margin | (598.56%) | 54.82% | 0.00% |
| Free cash flow margin | (173.76%) | 58.52% | 0.00% |
| Return on equity | 122.85% | 20.12% | (56.36%) |
| Return on assets | (192.58%) | 18.30% | (48.04%) |
| Return on invested capital | 0.00% | 24.07% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack